Study of the possible medical and medication explanatory factors of angiographic outcomes in patients with acute ST elevation myocardial infarction undergoing primary percutaneous intervention


1 Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti ; Students Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Department of Clinical Pharmacy, Faculty of Pharmacy; Department of cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran

3 Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4 Kermanshah University of Medical Sciences, Kermanshah, Iran

5 Department of cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran

6 Department of pharmacology, Applid Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

7 Department of Radiology, Tabriz University of Medical Science, Tabriz, Iran


Background: Myocardial blush grade (MBG), thrombolysis in myocardial infarction (TIMI) and corrected TIMI frame count (cT F C) are indices of successful angiographic reperfusion. This study sought to determine the predictors of angiographically successful reperfusion including demographic, clinical and angiographic factors in patients with ST elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI).
Materials and Methods: A cross-sectional study of patients with a confirmed diagnosis of STEMI undergoing pPCI was designed. Eligible patients referring to a university heart center were enrolled in the study from March 2012 to December 2012. Successful epicardial reperfusion was defned as TIMI flow grade 3 or cTFC<= 28 frames and successful myocardial reperfusion as MBG 2 or 3.
Results: The study population consisted of 100 patients, including 74 males and 26 females, with mean ± standard deviation age of 58.27 ± 11.60 years. Achieving open microvasculature (MBG 2/3) was positively associated with a history of nitrate intake (P = 0.03) and history of calcium channel blocker (CCB) intake (P = 0.005). Hyperglycemia was inversely associated with achieving a final cTFC ≤ 28 frames (r = −0.32, P = 0.001).
Conclusions: Our findings suggest that patients with a history of nitrate and CCB intake had a higher likelihood of successful PCI. In addition, patients with a higher blood glucose level on admission may have a reduced rate of reperfusion success. Future studies with a larger sample size are recommended to investigate the significant relationships observed in this study.


1. Kushner FG, Hand M, Smith SC Jr, King SB 3 rd , Anderson JL, Antman EM, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205-41.  Back to cited text no. 1
2. Henriques JP, Zijlstra F, Ottervanger JP, de Boer MJ, van 't Hof AW, Hoorntje JC, et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J 2002;23:1112-7.  Back to cited text no. 2
3. Boersma E, Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006;27:779-88.  Back to cited text no. 3
4. van't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: Myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998;97:2302-6.  Back to cited text no. 4
5. Stone GW, Peterson MA, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol 2002;39:591-7.  Back to cited text no. 5
6. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: A quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88.  Back to cited text no. 6
7. Gibson CM, Schömig A. Coronary and myocardial angiography: Angiographic assessment of both epicardial and myocardial perfusion. Circulation 2004;109:3096-105.  Back to cited text no. 7
8. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985;312:932-6.  Back to cited text no. 8
9. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001;103:3019-41.  Back to cited text no. 9
10. Hamada S, Nishiue T, Nakamura S, Sugiura T, Kamihata H, Miyoshi H, et al. TIMI frame count immediately after primary coronary angioplasty as a predictor of functional recovery in patients with TIMI 3 reperfused acute myocardial infarction. J Am Coll Cardiol 2001;38:666-71.  Back to cited text no. 10
11. Tillmanns H, Neumann FJ, Parekh N, Waas W, Möller P, Zimmermann R, et al. Calcium antagonists and myocardial microperfusion. Drugs 1991;42 Suppl 1:1-6.  Back to cited text no. 11
12. Reimer KA, Jennings RB. Effects of calcium-channel blockers on myocardial preservation during experimental acute myocardial infarction. Am J Cardiol 1985;55:107B-15.  Back to cited text no. 12
13. Ehring T, Heusch G. Dihydropyridine calcium antagonists: Beneficial or adverse effects in the setting of myocardial ischaemia/reperfusion? Cardiology 1997;88 Suppl 1:3-14.  Back to cited text no. 13
14. Pepine CJ. The role of calcium antagonists in ischaemic heart disease. Eur Heart J 1995;16 Suppl H:19-24.  Back to cited text no. 14
15. Folts JD. Inhibition of platelet activity in vivo by amlodipine alone and combined with aspirin. Int J Cardiol 1997;62 Suppl 2:S111-7.  Back to cited text no. 15
16. Demir I, Yilmaz H, Ermis C, Sancaktar O. Treatment of no-reflow phenomenon with verapamil after primary stent deployment during myocardial infarction. Jpn Heart J 2002;43:573-80.  Back to cited text no. 16
17. Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002;57:444-51.  Back to cited text no. 17
18. Dens J, Desmet W, Piessens J. An updated meta-analysis of calcium-channel blockers in the prevention of restenosis after coronary angioplasty. Am Heart J 2003;145:404-8.  Back to cited text no. 18
19. ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: The ENCORE I Study (evaluation of nifedipine and cerivastatin on recovery of coronary endothelial function). Circulation 2003;107:422-8.  Back to cited text no. 19
20. Michaels AD, Appleby M, Otten MH, Dauterman K, Ports TA, Chou TM, et al. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: Results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol 2002;14:299-302.  Back to cited text no. 20
21. Aoki M, Sakai K, Koyanagi S, Takeshita A, Nakamura M. Effect of nitroglycerin on coronary collateral function during exercise evaluated by quantitative analysis of thallium-201 single photon emission computed tomography. Am Heart J 1991;121:1361-6.  Back to cited text no. 21
22. Göller V, Clausen M, Henze E, Giesler M, Schmidt A, Kochs M, et al. Reduction of exercise-induced myocardial perfusion defects by isosorbide-5-nitrate: Assessment using quantitative Tc-99m-MIBI-SPECT. Coron Artery Dis 1995;6:245-9.  Back to cited text no. 22
23. Stegaru B, Loose R, Keller H, Buss J, Wetzel E. Effects of long-term treatment with 120 mg of sustained-release isosorbide dinitrate and 60 mg of sustained-release nifedipine on myocardial perfusion. Am J Cardiol 1988;61:74E-7.  Back to cited text no. 23
24. Lewin HC, Hachamovitch R, Harris AG, Williams C, Schmidt J, Harris M, et al. Sustained reduction of exercise perfusion defect extent and severity with isosorbide mononitrate (Imdur) as demonstrated by means of technetium 99m sestamibi. J Nucl Cardiol 2000;7:342-53.  Back to cited text no. 24
25. Mahmarian JJ, Fenimore NL, Marks GF, Francis MJ, Morales-Ballejo H, Verani MS, et al. Transdermal nitroglycerin patch therapy reduces the extent of exercise-induced myocardial ischemia: Results of a double-blind, placebo-controlled trial using quantitative thallium-201 tomography. J Am Coll Cardiol 1994;24:25-32.  Back to cited text no. 25
26. Zoghbi GJ, Dorfman TA, Iskandrian AE. The effects of medications on myocardial perfusion. J Am Coll Cardiol 2008;52:401-16.  Back to cited text no. 26
27. Ambrosio G, Del Pinto M, Tritto I, Agnelli G, Bentivoglio M, Zuchi C, et al. Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: Insights from 52,693 patients in the Global Registry of Acute Coronary Events. Eur Heart J 2010;31:430-8.  Back to cited text no. 27
28. Timóteo AT, Mamede A, de Lurdes Ferreira M, Serra J, Oliveira JA, Ferreira RC, et al. Is chronic nitrate therapy associated with a different clinical presentation of acute coronary syndrome? Rev Port Cardiol 2007;26:135-43.  Back to cited text no. 28
29. Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, Havranek EP, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: Implications for patients with and without recognized diabetes. Circulation 2005;111:3078-86.  Back to cited text no. 29
30. Marenzi G, De Metrio M, Rubino M, Lauri G, Cavallero A, Assanelli E, et al. Acute hyperglycemia and contrast-induced nephropathy in primary percutaneous coronary intervention. Am Heart J 2010;160:1170-7.  Back to cited text no. 30
31. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999;34:146-54.  Back to cited text no. 31
32. Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003;41:1-7.  Back to cited text no. 32
33. Nurkalem Z, Hasdemir H, Ergelen M, Aksu H, Sahin I, Erer B, et al. The relationship between glucose tolerance and severity of coronary artery disease using the Gensini score. Angiology 2010;61:751-5.  Back to cited text no. 33
34. Shen XH, Jia SQ, Li HW. The influence of admission glucose on epicardial and microvascular flow after primary angioplasty. Chin Med J (Engl) 2006;119:95-102.  Back to cited text no. 34
35. Nakamura T, Ako J, Kadowaki T, Funayama H, Sugawara Y, Kubo N, et al. Impact of acute hyperglycemia during primary stent implantation in patients with ST-elevation myocardial infarction. J Cardiol 2009;53:272-7.  Back to cited text no. 35
36. Yildiz A, Arat-Ozkan A, Kocas C, Abaci O, Coskun U, Bostan C, et al. Admission hyperglycemia and TIMI frame count in primary percutaneous coronary intervention. Angiology 2012;63:325-9.  Back to cited text no. 36
37. Kondo M, Nakano A, Saito D, Shimono Y. Assessment of "microvascular no-reflow phenomenon" using technetium-99 m macroaggregated albumin scintigraphy in patients with acute myocardial infarction. J Am Coll Cardiol 1998;32:898-903.  Back to cited text no. 37
38. Henriques JP, Zijlstra F, van 't Hof AW, de Boer MJ, Dambrink JH, Gosselink M, et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation 2003;107:2115-9.  Back to cited text no. 38
39. Fokkema ML, Wieringa WG, van der Horst IC, Boersma E, Zijlstra F, de Smet BJ. Quantitative analysis of the impact of total ischemic time on myocardial perfusion and clinical outcome in patients with ST-elevation myocardial infarction. Am J Cardiol 2011;108:1536-41.  Back to cited text no. 39
40. Celik T, Kursaklioglu H, Iyisoy A, Kose S, Kilic S, Amasyali B, et al. The effects of prior use of atorvastatin on coronary blood flow after primary percutaneous coronary intervention in patients presenting with acute myocardial infarction. Coron Artery Dis 2005;16:321-6.  Back to cited text no. 40
41. Lev EI, Kornowski R, Vaknin-Assa H, Ben-Dor I, Brosh D, Teplitsky I, et al. Effect of previous treatment with statins on outcome of patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 2009;103:165-9.  Back to cited text no. 41
42. Blankenship JC, Haldis T, Feit F, Hu T, Kleiman NS, Topol EJ, et al. Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy). Am J Cardiol 2006;97:1591-6.  Back to cited text no. 42
43. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: Results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49:1272-8.  Back to cited text no. 43